Search - tctmd.com

Displaying 1 - 20 of 75

Sort: Relevancy | Date

ESC Guidelines Update Clarifies Pregnancy Risks and Choices in Women With CVD

News Conference News ESC 2025

ESC Guidelines Update Clarifies Pregnancy Risks and Choices in Women With CVD

September 09, 2025

HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients

News Conference News ESC 2025

HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients

September 01, 2025

AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC

News Conference News ESC 2025

AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC

September 01, 2025

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

News Conference News ACC 2025

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

March 29, 2025

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

News Conference News VIVA 2024

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

November 11, 2024

Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II

News Conference News VIVA 2024

Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II

November 06, 2024

Temporary Pacemaker After TAVI May Preclude Long-term Pacing

News Conference News EuroPCR 2024

Temporary Pacemaker After TAVI May Preclude Long-term Pacing

May 24, 2024

POLMIDES: Hybrid Revascularization Bests CABG For 10-Year Survival

News Conference News EuroPCR 2024

POLMIDES: Hybrid Revascularization Bests CABG For 10-Year Survival

Yael L. Maxwell

May 22, 2024

Medicare Analysis Suggests Benefit of PFO Closure Beyond Age 60

News Conference News ESOC 2024

Medicare Analysis Suggests Benefit of PFO Closure Beyond Age 60

May 17, 2024

Latest TAVI vs Surgery Trial Raises Eyebrows in Aortic Stenosis Plus CAD

News Conference News EuroPCR 2024

NOW PUBLISHED - Latest TAVI vs Surgery Trial Raises Eyebrows in Aortic Stenosis Plus CAD

Michael O'Riordan

May 14, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

Debating the Role of T-TEER in the Sickest Patients

News Conference News THT 2024

Debating the Role of T-TEER in the Sickest Patients

Michael O'Riordan

March 05, 2024

Assisted Reproductive Technology Linked to Higher Stroke Risk

News Conference News ISC 2024

Assisted Reproductive Technology Linked to Higher Stroke Risk

February 07, 2024

Will IVUS Ever Take Off in Peripheral Vascular Interventions?

News Conference News ISET 2024

Will IVUS Ever Take Off in Peripheral Vascular Interventions?

January 31, 2024

AI in Pulmonary Embolism: ‘Transformative’ for Patient Care

News Conference News ISET 2024

AI in Pulmonary Embolism: ‘Transformative’ for Patient Care

January 30, 2024

Venous Stents: How to Choose Among the Wealth of Options

News Conference News ISET 2024

Venous Stents: How to Choose Among the Wealth of Options

January 26, 2024

Intermittent Coronary Sinus Occlusion Fails to Cut Infarct Size in STEMI

News Conference News TCT 2023

Intermittent Coronary Sinus Occlusion Fails to Cut Infarct Size in STEMI

Yael L. Maxwell

November 06, 2023

PROMISE II: Deep-Vein Arterialization Durable for Amputation-Free Survival in CLTI

News Conference News VIVA 2023

PROMISE II: Deep-Vein Arterialization Durable for Amputation-Free Survival in CLTI

November 01, 2023

WATCH-TAVR: Adding LAAO to TAVI No Worse Than TAVI Alone

News Conference News TCT 2023

WATCH-TAVR: Adding LAAO to TAVI No Worse Than TAVI Alone

October 24, 2023

ONCO DVT Supports 12 Months of Preventive DOACs in Cancer Patients

News Conference News ESC 2023

ONCO DVT Supports 12 Months of Preventive DOACs in Cancer Patients

August 30, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.